Higher-riskArticle link

Why APOE Genotype Testing Is Required Before Starting Lecanemab

Before your loved one can begin lecanemab (Leqembi), the doctor will order a simple blood test called APOE genotyping. This test looks for a specific gene variant, APOE4, that dramatically raises the risk of a serious side effect called ARIA (brain swelling or small bleeds). Knowing your family member's APOE status helps the care team decide if the potential benefit of slowing Alzheimer's is worth the higher risk of ARIA. It is not a test for whether they 'have' Alzheimer's—it is a safety check, and there are clear steps you can take to prepare and understand the results.

Key points

  • APOE genotyping is a required safety test before starting lecanemab—it is not a diagnostic test for Alzheimer's.
  • People with one copy of APOE4 have about 4 times higher risk of ARIA; those with two copies have up to 14 times higher risk.
  • The test is a simple blood draw or cheek swab; results take 1–2 weeks.
  • Regular brain MRIs are needed to monitor for ARIA, especially in APOE4 carriers. The FDA recommends surveillance MRIs before the 5th, 7th, and 14th infusions (after baseline).
  • Blood thinners and certain supplements increase bleeding risk—always tell the doctor about all medications.
  • Knowing the APOE result helps you and the doctor make an informed decision about whether the benefit of slowing Alzheimer's outweighs the risk of serious side effects.

What Is APOE Genotyping and Why Is It Required?

APOE (apolipoprotein E) is a gene that comes in three common forms: APOE2, APOE3, and APOE4. Everyone inherits two copies—one from each parent. The APOE4 variant is strongly linked to a higher risk of developing Alzheimer's disease, but more importantly for this treatment, it also makes a person much more likely to experience a side effect called ARIA (amyloid-related imaging abnormalities). ARIA includes brain swelling (ARIA-E) and small brain bleeds (ARIA-H), which can be serious. The U.S. Food and Drug Administration (FDA) now recommends that anyone considering lecanemab or donanemab get tested for the APOE4 gene before starting treatment. This is not optional—it is a required safety step. The test itself is a simple blood draw or cheek swab, and results usually come back within a week or two.

How APOE Status Affects ARIA Risk

The risk of ARIA is not the same for everyone. People who carry one copy of APOE4 (called heterozygous, or APOE e3/e4) have about a 4 times higher risk of developing ARIA compared to those with no APOE4 copies (APOE e3/e3). Those who carry two copies (APOE e4/e4, or homozygous) have up to a 14 times higher risk. This is why the doctor will not start lecanemab without knowing your loved one's APOE status. If they carry one or two copies of APOE4, the care team will monitor them more closely with regular brain MRIs—often before each infusion—to catch any swelling or bleeding early. If they carry no copies, the risk is lower, but monitoring is still done. Knowing the result also helps you and the doctor weigh the modest benefit of slowing cognitive decline against the real possibility of a serious side effect.

What the Test Does NOT Tell You

It is important to understand that APOE genotyping is not a diagnostic test for Alzheimer's disease. It does not tell you whether your loved one has amyloid plaques in their brain—that requires a separate test like an amyloid PET scan or a spinal fluid analysis. The APOE test only reveals genetic risk for ARIA and for developing Alzheimer's later in life. Many people with APOE4 never develop Alzheimer's, and many without it do. The test is used solely for treatment safety, not for diagnosis or prognosis. Your doctor will explain the results in the context of your family member's overall health and treatment plan.

General caregiving information, not medical advice. Check medications and major care changes with your clinician.

Step-by-step

  1. Ask the neurologist or memory clinic doctor: 'Is APOE genotyping required before starting lecanemab for my family member?' They will confirm that it is standard practice and will order the test.

  2. Schedule the blood draw or cheek swab. The test is usually done at a lab or during a routine visit. No special preparation is needed—no fasting or stopping medications.

  3. Wait for the results, which typically take 5–14 days. During this time, ask the doctor: 'What will the results mean for my loved one's treatment plan? How will you use the APOE status to adjust monitoring?'

  4. When results come back, ask for a clear explanation: 'What is their APOE genotype? Does it mean they have zero, one, or two copies of APOE4? What does that mean for their ARIA risk?'

  5. If your loved one carries one or two copies of APOE4, discuss the increased risk of ARIA. Ask: 'How often will we do brain MRIs? What symptoms should I watch for at home that could indicate ARIA?'

  6. If they carry no copies (APOE e3/e3), the risk is lower but not zero. Ask: 'What is the baseline MRI schedule? What are the early warning signs of ARIA even with low risk?'

  7. Before starting lecanemab, ensure your loved one has a baseline brain MRI. The FDA recommends surveillance MRIs before the 5th, 7th, and 14th infusions (in addition to any clinically indicated scans) to monitor for ARIA. If your loved one's doctor suggests a different schedule, ask for the reasoning and document it.

  8. If your loved one is on blood thinners (like warfarin, apixaban, or clopidogrel), tell the doctor immediately. Blood thinners increase the risk of brain bleeding with lecanemab. The doctor may need to adjust or pause the blood thinner before starting treatment. Do not stop or change any blood thinner without explicit instructions from the prescribing doctor.

  9. Document any new symptoms after starting lecanemab: headache, confusion, vision changes, nausea, or difficulty walking. Report these to the doctor right away, as they could be signs of ARIA.

  10. Keep a written log of all medications, including over-the-counter supplements (like vitamin E, fish oil, or ginkgo biloba), and share it with the neurologist. Some supplements can also increase bleeding risk.

What not to do

  • Do not assume that a family history of Alzheimer's means your loved one has APOE4. The gene is inherited, but many people with a strong family history do not carry APOE4. Testing is the only way to know.

  • Do not skip the APOE test because you are worried about the emotional impact of knowing genetic risk. The test is required for safety, not for predicting the future. Discuss any anxiety with a genetic counselor before the test.

  • Do not start lecanemab without a baseline MRI. Even if your loved one has no symptoms, ARIA can occur silently. The MRI is the only way to detect it early.

  • Do not stop or change blood thinners without explicit instructions from the prescribing doctor. Abruptly stopping a blood thinner can cause a stroke or heart attack. The doctor will guide you on a safe plan.

  • Do not ignore new symptoms like a sudden headache, confusion, or vision changes after an infusion. These can be early signs of ARIA. Call the doctor or go to the emergency room immediately.

  • Do not compare your loved one's APOE result to other family members' results without professional interpretation. The same genotype can have different implications depending on age, health, and other risk factors.

Practical tools

  • APOE Result Discussion Script

    When the doctor shares the APOE result, use this script: 'Thank you for explaining. Can you please tell me the exact genotype? Is it e3/e3, e3/e4, or e4/e4? What does that mean for my loved one's risk of ARIA? How will this change the monitoring schedule? What specific symptoms should I watch for at home?' Write down the answers and keep them in a care notebook.

  • ARIA Symptom Checklist

    Print or save this checklist to review after each infusion: (1) New or worsening headache? (2) Confusion or disorientation? (3) Vision changes (blurring, double vision)? (4) Nausea or vomiting? (5) Difficulty walking or balance problems? (6) Seizures? If any are present, call the neurologist immediately. Keep this list in your phone or on the fridge.

  • Medication and Supplement Review Sheet

    Before starting lecanemab, create a one-page list of all medications and supplements your loved one takes, including dose and frequency. Include blood thinners, aspirin, NSAIDs (ibuprofen, naproxen), vitamin E, fish oil, ginkgo biloba, and any herbal products. Share this with the neurologist and ask: 'Does any of these increase the risk of bleeding with lecanemab? Should any be stopped or adjusted?'

  • Genetic Counseling Referral

    If you or your loved one feels anxious about the APOE result, ask for a referral to a genetic counselor. They can explain the implications in a neutral, supportive way and help you understand how the result affects treatment decisions without causing unnecessary worry. Many memory clinics have a counselor on staff or can recommend one.

  • Baseline MRI Preparation Guide

    Before the first MRI, ask the doctor: 'Will this MRI be used as a baseline to compare with future scans? How often will we repeat it? What will you look for on the scan?' Write down the date and results. Keep a copy of the radiology report in your care binder.

  • Infusion Day Communication Card

    Create a small card your loved one can carry or you can show the infusion nurse: 'My family member is taking lecanemab. Their APOE genotype is [e3/e3 or e3/e4 or e4/e4]. Please monitor for ARIA symptoms during and after the infusion. Call the neurologist if any new symptoms appear.' This ensures everyone on the care team is aware of the risk.

Discuss with your clinician

Ask the neurologist: 'What is the exact ARIA risk for my loved one based on their APOE genotype? Can you give me a percentage or a range?'

Ask: 'If my loved one develops ARIA, what is the treatment? Do we stop the drug temporarily or permanently? What is the recovery time?'

Ask: 'How will we coordinate with the doctor who prescribes their blood thinner? Who will be responsible for managing that medication during lecanemab treatment?'

Ask: 'Are there any other genetic tests (like for the F5 gene related to blood clots) that might be relevant before starting lecanemab?'

Ask: 'If my loved one has a history of migraines, seizures, or other neurological conditions, does that change the risk of ARIA?'

Ask: 'What is the plan if my loved one misses an MRI or an infusion? How does that affect safety?'

Ask: 'What is the exact MRI monitoring schedule recommended for my loved one based on the latest FDA prescribing information? Can you confirm the timing of surveillance scans?'

Related guides

Sources